Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues

European Journal of Dermatology

Volumn 18, Issue 1, 2008, Pages 6-10

  Quatresooz, Pascale ^a   Piérard Franchimont, Claudine ^a   Paquet, Philippe ^a   Hubert, Pascale ^a   Delvenne, Philippe ^a   Piérard, Gérald E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Actinic keratosis; Diclofenac; Epidermal growth factor receptor; Imidazoquinoline; MAL photodynamic therapy; Squamous cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; ANTIPYRETIC ANALGESIC AGENT; CETUXIMAB; DICLOFENAC PLUS HYALURONAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; SORAFENIB; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; CLINICAL FEATURE; CLINICAL TRIAL; DYSESTHESIA; ERYTHEMA; HISTOPATHOLOGY; HUMAN; PHOTODYNAMIC THERAPY; PREVALENCE; PRURITUS; REVIEW; SQUAMOUS CELL CARCINOMA; XEROSIS;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATOSIS; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; SUNLIGHT;

EID: 38549100212     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0303     Document Type: Review

References (76)

1. Glogau R. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23-4.
2. Person JR. An actinic keratosis is neither malignant nor premalignant: it is an initiated tumor. J Am Acad Dermatol 2003; 48: 637-8.
3. Smoller BR. Squamous cell carcinoma: from precursor lesions to high-risk variants. Mod Pathol 2006; 19: S88-S92.
4. Hurt MA. The nature of solar (actinic) keratosis. Br J Dermatol 2007; 156: 408-9.
5. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000; 42: 11-7.
6. Ackerman AB. Actinic keratoses, malignant or not? J Am Acad Dermatol 2001; 45: 466-9.
7. Cockerell CJ. Pathology and pathobiology of actinic (solar) keratosis. Br J Dermatol 2003; 149: S34-S36.
8. st-century perspective. Arch Dermatol 2003; 139: 66-70.
9. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22.
10. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective. Arch Dermatol 1991; 127: 1029-31.
11. Wheeland RG. The pitfalls of treating all actinic keratoses as squamous cell carcinomas. Semin Cutan Med Surg 2005; 24: 152-4.
12. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses. I- Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 1302-7.
13. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677-81.
14. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in Merseyside population. Br J Dermatol 2000; 142: 1154-9.
15. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4-7.
16. Uhoda I, Quatresooz P, Fumal I, Nikkels AF, Piérard-Franchimont C, Piérard GE. Updating trends in cutaneous cancers in south-east Belgium. Oncol Rep 2004; 12: 111-4.
17. Araki K, Nagano T, Ueda M, Washio F, Watanabe S, Yamaguchi N, et al. Incidence of skin cancers and precancerous lesions in Japanese-risk factors and prevention. J Epidemiol 1999; 9: S14-S21.
18. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-7.
19. Marks R, Rennie G, Selwood TS. The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses. Arch Dermatol 1988; 124: 1039-42.
20. Carag HR, Prieto VG, Yballe LS, Shea CR. Utility of step sections: demonstration of additional pathological findings in biopsy samples initially diagnosed as actinic keratosis. Arch Dermatol 2000; 136: 471-5.
21. Anwar J, Wrone DA, Kimyai-Asdi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol 2004; 22: 189-96.
22. Einspahr JG, Alberts DS, Warneke JA, Bozzo P, Basye J, Grogan TM, et al. Relationship of p53 mutation to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia 1999; 1: 468-75.
23. INK4a tumor suppressor. Cancer Lett 2002; 176: 205-14.
24. Filipowicz E, Adegboyega P, Sanchez RL, Gatalica Z. Expression of CD95 (Fas) in sun-exposed human skin and cutaneous carcinomas. Cancer 2002; 94: 814-9.
25. Ramzi ST, Maruno M, Khaskhely NM, Khan MA, Takamiyagi A, Uezato H, et al. An assessment of the malignant potential of actinic keratoses and Bowen's disease: p53 and PCNA expression pattern correlate with the number of desmosomes. J Dermatol 2002; 29: 562-72.
26. Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol 2003; 139: 876-82.
27. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-30.
28. Uhoda I, Quatresooz P, Piérard-Franchimont C, Piérard GE. Nudging epidermal field cancerogenesis by imiquimod. Dermatology 2003; 206: 357-60.
29. Quatresooz P, Petit L, Uhoda I, Piérard-Franchimont C, Piérard GE. Mosaic subclinical melanoderma. An Achilles heel for UV-related epidermal carcinogenesis? Int J Oncol 2004; 25: 1763-7.
30. Matsumara Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV radiation of skin: implications for molecular medicine. Expert Rev Mol Med 2002; 2002: 1-22.
31. Paquet P, Piérard GE. Invasive atypical fibroxanthoma and eruptive actinic keratoses in a heart transplant patient. Dermatology 1996; 192: 411-3.
32. Euvrard S, Kanitakis J, Claudy A. Skin cancers in organ transplant recipients. N Engl J Med 2003; 348: 1681-91.
33. Tomas D, Kruslin B, Cupic H, Stanimirovic A, Bosnjak B, Lovricevic I, Belicza M. Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis. J Eur Acad Dermatol Venereol 2006; 20: 51-7.
34. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: S8-S10.
35. Quaedvlieg PJF, Tirsi E, Thissen MRTM, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16: 335-9.
36. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002; 146: 810-5.
37. Guenthner ST, Hurwitz RM, Buckle IJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation. J Am Acad Dermatol 1999; 41: 443-8.
38. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42: 525-8.
39. Jeffes WB, Tang EG. Actinic keratosis: current treatment options. Am J Clin Dermatol 2000; 1: 167-79.
40. Berman B, Villar AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol 2006; 5: 167-73.
41. Gold MH, Nestor MS. Current treatments of actinic keratosis. J Drugs Dermatol 2006; 5: S17-S25.
42. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599-606.
43. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006; 31: 783-5.
44. Hermanns JF, Piérard GE, Quatresooz P. Erlotinib-responsive actinic keratosis. Oncol Rep 2007; 18: 581-4.
45. Scurry J. Grading of actinic keratosis. J Am Acad Dermatol 2001; 44: 1052-3.
46. Epstein E. Quantifying actinic keratosis: assessing the evidence. Am J Clin Dermatol 2004; 5: 141-4.
47. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-7.
48. Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003; 149: S5-S8.
49. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498-502.
50. Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004; 9: 291-8.
51. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004; 140: 1542.
52. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9: 209-14.
53. Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
54. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006; 55: 537-8.
55. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006; 126: 1251-5.
56. Ulrich C, Busch JO, Meyer T, Nindl I, Schmook T, Sterry W, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006; 155: 451-4.
57. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-41.
58. Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-8.
59. Ben M'barek L, Mebazaa A, Euvrard S, et al. 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007; 215: 130-3.
60. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.
61. Quatresooz P, Piérard GE. Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin Exp Dermatol 2003; 28: S27-S29.
62. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.
63. Wolf Jr. JE, Taylor JR, Tschen E, Kang S. Topical 3,0 % diclotenac in 2,5 % hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
64. Adamson DJA, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome proliferators-activated receptor-γ signalling. Mol Pharmacol 2002; 61: 7-12.
65. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Paulin Y. Topical treatment of actinic keratoses with 3.0 % diclofenac in 2, % hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
66. Jarvis B, Figgit DP. Topical 3% diclofenac in a 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 2003; 4: 203-13.
67. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3% diclofenac sodium topical gel (Solaraze™). J Drugs Dermatol 2004; 3: 401-7.
68. Pirard D, Vereecken P, Mélot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratosis: a meta-analysis of the recent studies. Arch Dermatol 2005; 297: 185-9.
69. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-9.
70. Pariser DM, Lowe NJ, Stewart DM, Jarrat MT, Lucky AW, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-32.
71. Babilas P, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology. Eur J Dermatol 2006; 16: 340-8.
72. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-43.
73. Siddiqui MAA, Perry CM, Scott LJ. Topical methyl aminolevulinate. Am J Clin Dermatol 2004; 5: 127-37.
74. Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate (Metvix®) is effective and safe in the treatment of actinic keratosis: results of a prospective randomized trial. J Am Acad Dermatol 2003; 48: 227-32.
75. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinto PG, Zane C, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62.
76. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodymic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat 2003; 14: 99-106.